Abstract
Background
The relationship between serum low-density lipoprotein cholesterol (LDL-C) and the risk of relapse in neuromyelitis optica spectrum disorder (NMOSD) remains uncertain. We aimed to examine the association between serum LDL-C level and relapse in NMOSD patients.Methods
We conducted an analysis of the prospective observational NMOSD cohort study with consecutive 184 hospitalized NMOSD patients from department of neurology. Blood samples were collected to measure LDL-C level upon admission. Primary and relapse were evaluated during hospitalization. The relationship between serum LDL-C level and relapse were analyzed by linear curve fitting analyses. Crude and adjusted odds ratios (OR) of LDL-C for relapse with 95% confidence intervals were analyzed using multiple logistic regression models. ROC curve analysis was used to identify the target lipid-lowering value of LDL-C and the probability of relapse was evaluated by the Kaplan-Meier Plot.Results
Over a mean disease course of 100±87 days, 59.24% (n=109) participants developed relapse with higher LDL-C than the primary group (n=75) (p<0.001). Adjusted smoothed plots suggested that there were linear relationships between serum LDL-C level and relapse (p< 0.001). The OR (95% CI) between serum LDL-C level and relapse were 2.67 (1.76-4.04, p<0.001), and 2.38 (1.48-3.83, p<0.001) respectively in NMOSD patients before and after adjusting for potential confounders. The target LDL-C lowering values were 2.795 mmol/L with potential benefits to prevent relapse in NMOSD.Conclusion
In this sample of NMOSD patients, we found that the elevated serum LDL-C was independently and positively associated with the relapse, and serum LDL-C should be well-controlled to prevent the relapse of NMOSD.References
Articles referenced by this article (43)
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
J Neurol Neurosurg Psychiatry, (11):1186-1191 2013
MED: 23595944
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis.
Neurology, (13):1041-1047 2010
MED: 20350978
The differential expression of natural killer cells in NMOSD and MS.
J Clin Neurosci, 9-14 2019
MED: 31864829
Lipid rafts and neurodegeneration: structural and functional roles in physiologic aging and neurodegenerative diseases.
J Lipid Res, (5):636-654 2019
MED: 31871065
SREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington's disease phenotypes.
Brain, (10):3175-3190 2021
MED: 33974044
Impairing committed cholesterol biosynthesis in white matter astrocytes, but not grey matter astrocytes, enhances in vitro myelination.
J Neurochem, (5):624-641 2020
MED: 32602556
Triglyceride Level Is an Independent Risk Factor in First-Attacked Neuromyelitis Optica Spectrum Disorders Patients.
Front Neurol, 1230 2019
MED: 31824407
High serum creatinine is associated with reduction of vision impaired in patients with NMOSD.
J Neuroimmunol, 32-37 2017
MED: 28778442
Oxidized low-density lipoproteins induce tissue factor expression in T-lymphocytes via activation of lectin-like oxidized low-density lipoprotein receptor-1.
Cardiovasc Res, (6):1125-1135 2020
MED: 31504248
Serum lipoprotein levels in patients with neuromyelitis optica elevated but had little correlation with clinical presentations.
Clin Neurol Neurosurg, (6):478-481 2010
MED: 20399007
Show 10 more references (10 of 43)